EATRIS is pleased to announce it has joined forces and entered into a long-term collaboration agreement with CERN that promises to unleash new opportunities in translational medicine. By combining their complementary expertise to develop advanced technologies in areas of high medical need, this partnership is poised to pave the way for ground-breaking advancements in the field of healthcare.
CERN, the European Laboratory for Particle Physics, is operating the world’s largest and most powerful particle accelerator. Its core mission is to provide cutting-edge technology and indispensable infrastructure to perform world-class research in fundamental physics by hosting numerous international collaborations that have led to revolutionary experiments and technological developments. Notably, CERN is also credited as the birthplace of the World Wide Web.
EATRIS, the European infrastructure for translational medicine, brings together resources and services for research communities to accelerate the translation of scientific discoveries into benefit for patients. The organisation provides access to a vast array of expertise and facilities from over 150 top-tier academic centres across Europe.
Toni Andreu, EATRIS Scientific Director, expressed his enthusiasm with the agreement, stating: “EATRIS and CERN are joining forces to accelerate the translation of scientific discoveries into tangible healthcare interventions for unmet medical needs. The expertise of both organisations will create a novel framework for cooperation where scientists from different disciplines will help each other to accelerate the development of new solutions for people who suffer from devastating diseases. This is an exciting example of how science, and research infrastructures, are key drivers for making a better society.”
Alessandro Raimondo (Medical Applications Officer at CERN) comments: “We are excited about this collaboration and bringing CERN’s world-class research expertise to the table with EATRIS. This long-term collaboration agreement holds the promise of having a meaningful impact on unmet medical needs, ultimately leading to a healthier future for all. We look forward to seeing the positive outcomes of our combined efforts in the world of translational medicine.”
Sara Zullino (EATRIS Scientific & SME Outreach Manager) adds: “Through this partnership, EATRIS and CERN are set to propel the field of healthcare into uncharted territories. This collaboration aims to transfer the knowledge generated at CERN to society and pioneer new frontiers in health solutions. Together, we are embarking on a translational journey to revolutionise the way we approach scientific innovation and impact patients’ lives.”
Both organisations will leverage their infrastructure and technology platforms to support collaborative research initiatives and foster interdisciplinary projects, such as the recently launched TRUSTroke EU project.
This alliance between EATRIS and CERN marks a significant milestone in translational medicine and scientific collaboration, and bridging the gap between fundamental physics, research and healthcare intervention.
Under this agreement, joint workshops, symposiums, and conferences will be organised to cultivate innovative projects and facilitate knowledge dissemination.
About EATRIS:
EATRIS is the European infrastructure for translational medicine that brings together resources and services for research communities to translate scientific discoveries into benefits for patients. The organisation is a non-profit that provides access to a vast array of expertise and facilities from over 150 top-tier academic centres across Europe. EATRIS focuses on improving and optimising preclinical and early clinical development of drugs, vaccines and diagnostics, and overcome barriers to health innovation.
About CERN:
CERN, the European Organization for Nuclear Research, is one of the world’s leading laboratories for particle physics. The Organization is located on the French-Swiss border, with its headquarters in Geneva. Its Member States are: Austria, Belgium, Bulgaria, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and the United Kingdom. Cyprus, Estonia and Slovenia are Associate Member States in the pre-stage to Membership. Croatia, India, Latvia, Lithuania, Pakistan, Türkiye and Ukraine are Associate Member States. Japan and the United States of America currently have Observer status, as do the European Union and UNESCO. The Observer status of the Russian Federation and of JINR is suspended in accordance with the CERN Council Resolutions of 8 March 2022 and 25 March 2022, respectively.
Media Contacts:
EATRIS
Dr Jake Fairnie
Email: jakefairnie@eatris.eu
CERN
CERN Press Office
Email: press@cern.ch
